Sèvre Biologie x Biogroup

The respective long-time shareholders of Biomélis, Réseau Bio and Sèvre Biologie have chosen to merge with Biogroup. Biomélis, Réseau Bio and Sèvre Biologie, which operate a total of 14 laboratories in the Loire region, generated a combined turnover of €18 million in 2018.

The shareholders of these three independent laboratories, who wanted to join forces with a major partner, appointed PAX Corporate Finance to structure the operation. At the end of a competitive process, Biogroup came out on top thanks to the best valuation and medical project combination for the Loire region biologists.

Majority owned by Dr Stéphane Eimer, Biogroup offers routine and specialty analyses and, excluding these three acquisitions, operates more than 570 medical biology laboratories located mainly in eastern France (Alsace, Lorraine, Franche-Comté and Bourgogne), the Paris region, Provence-Alpes-Côte d’Azur, Rhône-Alpes, Limousin and Corsica. The group is the leading player in medical biology in France with pro-forma turnover of more than €700 million. It employs some 6,700 people, including more than 680 biologists.

The integration of Biomélis, Réseau Bio and Sèvre Biologie into Biogroup will allow the group to expand into western France by penetrating the Loire region and consolidate its position as a leader in medical biology in France. Biogroup’s future development in the region will be supported by the biologists of the acquired laboratories, who continue to hold a large stake in the company. In this way, the three laboratories are pursuing their local development while benefiting from significant synergies.

Pax Corporate Finance was the exclusive financial advisor to Biomélis, Réseau Bio and Sèvre Biologie in this transaction. This is the sixth transaction in six months in the medical biology sector for Pax Corporate Finance, which has established itself as the leading consultant in financial transactions for independent biologists.